Rong Du1,2,3, Delaney K Sullivan4, Nancy G Azizian1,2, Yuanhui Liu1,2, Yulin Li5,6. 1. Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, TX, 77030, USA. 2. Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA. 3. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. 4. UCLA-Caltech Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. 5. Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, TX, 77030, USA. yli@houstonmethodist.org. 6. Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA. yli@houstonmethodist.org.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers, is driven by oncogenic KRAS mutations. Farnesyl thiosalicylic acid (FTS), also known as salirasib, is a RAS inhibitor that selectively dislodges active RAS proteins from cell membrane, inhibiting downstream signaling. FTS has demonstrated limited therapeutic efficacy in PDAC patients despite being well tolerated. METHODS: To improve the efficacy of FTS in PDAC, we performed a genome-wide CRISPR synthetic lethality screen to identify genetic targets that synergize with FTS treatment. Among the top candidates, multiple genes in the endoplasmic reticulum-associated protein degradation (ERAD) pathway were identified. The role of ERAD inhibition in enhancing the therapeutic efficacy of FTS was further investigated in pancreatic cancer cells using pharmaceutical and genetic approaches. RESULTS: In murine and human PDAC cells, FTS induced unfolded protein response (UPR), which was further augmented upon treatment with a chemical inhibitor of ERAD, Eeyarestatin I (EerI). Combined treatment with FTS and EerI significantly upregulated the expression of UPR marker genes and induced apoptosis in pancreatic cancer cells. Furthermore, CRISPR-based genetic ablation of the key ERAD components, HRD1 and SEL1L, sensitized PDAC cells to FTS treatment. CONCLUSION: Our study reveals a critical role for ERAD in therapeutic response of FTS and points to the modulation of UPR as a novel approach to improve the efficacy of FTS in PDAC treatment.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers, is driven by oncogenic KRAS mutations. Farnesyl thiosalicylic acid (FTS), also known as salirasib, is a RAS inhibitor that selectively dislodges active RAS proteins from cell membrane, inhibiting downstream signaling. FTS has demonstrated limited therapeutic efficacy in PDACpatients despite being well tolerated. METHODS: To improve the efficacy of FTS in PDAC, we performed a genome-wide CRISPR synthetic lethality screen to identify genetic targets that synergize with FTS treatment. Among the top candidates, multiple genes in the endoplasmic reticulum-associated protein degradation (ERAD) pathway were identified. The role of ERAD inhibition in enhancing the therapeutic efficacy of FTS was further investigated in pancreatic cancer cells using pharmaceutical and genetic approaches. RESULTS: In murine and humanPDAC cells, FTS induced unfolded protein response (UPR), which was further augmented upon treatment with a chemical inhibitor of ERAD, Eeyarestatin I (EerI). Combined treatment with FTS and EerI significantly upregulated the expression of UPR marker genes and induced apoptosis in pancreatic cancer cells. Furthermore, CRISPR-based genetic ablation of the key ERAD components, HRD1 and SEL1L, sensitized PDAC cells to FTS treatment. CONCLUSION: Our study reveals a critical role for ERAD in therapeutic response of FTS and points to the modulation of UPR as a novel approach to improve the efficacy of FTS in PDAC treatment.
Entities:
Keywords:
Clusters of regularly interspaced short palindromic repeats (CRISPR); Endoplasmic reticulum-associated protein degradation (ERAD); Farnesyl thiosalicylic acid (FTS); Pancreatic ductal adenocarcinoma (PDAC); Salirasib; Unfolded protein response (UPR)
Authors: Hamsa Puthalakath; Lorraine A O'Reilly; Priscilla Gunn; Lily Lee; Priscilla N Kelly; Nicholas D Huntington; Peter D Hughes; Ewa M Michalak; Jennifer McKimm-Breschkin; Noburo Motoyama; Tomomi Gotoh; Shizuo Akira; Philippe Bouillet; Andreas Strasser Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta Journal: Nature Date: 2014-08-10 Impact factor: 49.962
Authors: Qiuyan Wang; Bidhan A Shinkre; Jin-gu Lee; Marc A Weniger; Yanfen Liu; Weiping Chen; Adrian Wiestner; William C Trenkle; Yihong Ye Journal: PLoS One Date: 2010-11-12 Impact factor: 3.240
Authors: Dharini van der Hoeven; Kwang-Jin Cho; Yong Zhou; Xiaoping Ma; Wei Chen; Ali Naji; Dina Montufar-Solis; Yan Zuo; Sarah E Kovar; Kandice R Levental; Jeffrey A Frost; Ransome van der Hoeven; John F Hancock Journal: Mol Cell Biol Date: 2018-01-16 Impact factor: 4.272
Authors: Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der Journal: Nat Med Date: 2019-03-04 Impact factor: 53.440